EANM 2023 – Vienna, Austria
Lecture Board: Burak Demir, MD; Phillip Kuo, MD, PhD, FACR; Dharmender Malik, MD; Irene Marini, MD; Magdalena Mileva, MD; Mercedes Mitjavila Casanovas, MD; Marta Opalińska, MD, PhD; Constantinos Zamboglou, MD
Medical Writer: Florence Boulmé, PhD; Christine Rous, PhD
Publishing Editor: Anna Fenzl, PhD
Preface – EANM 2023
Preface – EANM 2023 © Institut Jules Bordet – Magdalena Mileva, MD, Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium Dear Colleagues, The 36th annual congress of the European Association of Nuclear Medicine (EANM) was held in Vienna, Austria, and virtually from 9th to 13th September.
New developments in the diagnosis of neuroendocrine tumors
New developments in the diagnosis of neuroendocrine tumors Neuroendocrine neoplasms (NENs) comprise a rare group of heterogenous neoplasms that originate from cells with a neuroendocrine phenotype and can arise in almost every organ or region of the body [1]. They display a variable biological behavior; in fact, in some patients the disease may be stable for years, whereas in others, it might be very aggressive [2].
Recent progress in the treatment of neuroendocrine tumors
Recent progress in the treatment of neuroendocrine tumors Combined radioligand and CAPTEM therapy in patients with advanced, non-resectable, progressive GEP-NET Capecitabine plus temozolomide (CAPTEM) is widely used for the treatment of advanced, unresectable, and progressive neuroendocrine tumors (NETs).
Theranostics: recent developments in neuroendocrine tumors
Theranostics: recent developments in neuroendocrine tumors 225Ac-DOTATATE daughter nucleotide emissions RYZ101 (225Ac-DOTATATE) is a first-in-class alpha-emitting radiopharmaceutical being developed for somatostatin receptor-2-expressing (SSTR2+) solid tumors [1]. The ongoing phase 1b/3 ACTION-1 trial (NCT05477576) is currently comparing RYZ101 with standard therapy in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed after 177Lu-l
Early prediction of the response to 177Lu-PSMA therapy in metastatic prostate cancer
Early prediction of the response to 177Lu-PSMA therapy in metastatic prostate cancer PSMA (prostate-specific membrane antigen) is a glycoprotein highly expressed on the surface of malignant prostate tumor cells.
Advances in PSMA-based immunotherapy in metastatic castration-resistant prostate cancer
Advances in PSMA-based immunotherapy in metastatic castration-resistant prostate cancer Metastatic castration-resistant prostate cancer (mCRPC) has a very bad prognosis with most patients dying within two years of diagnosis [1].
Further benefits of PET imaging in prostate cancer
Further benefits of PET imaging in prostate cancer Prostate cancer was the most frequently diagnosed cancer in men in 112 countries around the world in 2020, with 1.4 million newly diagnosed cases leading to more than 375,000 deaths [1].
EANM 2022 – Barcelona, Spain
Lecture Board: Mercedes Mitjavila Casanovas, MD, PhD; Christophe Deroose, MD, PhD; Rick Hermsen, MD, PhD; Oana C. Kulterer, MD; Guillaume Nicolas, MD, PhD
Medical Writer: Vishal Hegde, PhD
Publishing Editor: Anna Fenzl, PhD
Preface – EANM 2022
Preface – EANM 2022 © private - Oana C. Kulterer, MD, Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria Dear Colleagues, After two years of virtual events, the nuclear medicine and oncology communities were excited to meet each other in person at the 35th Annual Congress of the European Association of Nuclear Medicine, held in Barcelona, Spain, and virtually from 15th – 19th October 2022. The event has cele
Recent progress in the treatment of neuroendocrine tumors
Recent progress in the treatment of neuroendocrine tumors Positive efficacy with 177Lu-octreotate in PanNET: Phase II OCLURANDOM Five systemic therapeutic options are currently approved for advanced pancreatic neuroendocrine tumors (PanNET): Streptozotocine-based chemotherapy, everolimus, sunitinib, lanreotide, and PRRT with 177Lu-DOTA-octreotate (OCLU).
Latest developments in prostate cancer treatment
Latest developments in prostate cancer treatment Favorable complementary mechanisms: 223RaCl2 followed by 177Lu-PSMA (RALU) The positive efficacy and safety data of 177Lu-PSMA-617 in the treatment of mCRPC patients from the Lu-PSMA and VISION trials led to its FDA approval and designation as a breakthrough therapy for later lines of mCRPC treatment [1,2].
Neuroendocrine tumor imaging updates
Neuroendocrine tumor imaging updates Little impact of interim PET/CT staging during PRRT for NETs Guideline recommendations for peptide receptor radionuclide therapy (PRRT) using 177Lu- DOTA-0-Tyr3-Octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs) include 3-5 cycles with a dose ranging from 5.5-7.4 GBq per cycle with 6-12 weeks intervals [1].
Advances in PSMA radiotracers for prostate cancer imaging
Advances in PSMA radiotracers for prostate cancer imaging [18F]DCFPyL tops [18F]Flurocholine in the recurrent setting: PYTHON Prostate-specific membrane antigen (PSMA)-targeting positron emission tomography/computed tomography (PET/CT) imaging is increasingly used to characterize prostate cancer (PCa).